One Pager as on January 30, 2026
![]() | Rule based diversification for optimum performance in changing market cycles |
![]() | Aim to provide stability of large caps and growth of mid caps |
![]() | Active stock selection through internal process framework for better return potential |
| Sector | MMLMCF* | NIFTY Large Midcap 250 TRI |
| Fast Moving Consumer Goods | 31.02% | 30.99% |
| Consumer Services | 14.31% | 6.45% |
| Automobile And Auto Components | 11.34% | 7.93% |
| Consumer Durables | 7.11% | 7.26% |
| Telecommunication | 6.08% | 8.50% |
*Mahindra Manulife Large & Mid Cap Fund
Data as on January 30, 2026
| Security | % to Net Assets |
| Indus Towers Limited | 4.51% |
| ICICI Bank Limited | 3.51% |
| Glenmark Pharmaceuticals Limited | 3.30% |
| UltraTech Cement Limited | 3.30% |
| HDFC Bank Limited | 3.05% |
| State Bank of India | 3.02% |
| Divi's Laboratories Limited | 2.76% |
| Infosys Limited | 2.72% |
| Reliance Industries Limited | 2.62% |
| IndusInd Bank Limited | 2.55% |
| Total | 31.34% |
| Fresh Additions | Complete Exits |
| Security | Security |
| HDFC Bank Limited | Mahindra Manulife Liquid Fund -Direct Plan Growth |
| Larsen & Toubro Limited | Central Depository Services (India) Limited |
| - | Dabur India Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio
changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager
may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult
their financial, tax and other advisors before taking any investment decision(s). Data as on January 30, 2026
| Turnover Ratio (Last 1 year) | 1.04 |
| Standard Deviation | 13.26% |
| Beta | 0.91 |
| Sharpe Ratio# | 0.89 |
| Jenson's Alpha | -0.0957 |
#Risk-free rate assumed to be 5.53% (MIBOR as on 30-01-2026) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on January 30, 2026
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Dec-19.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period. Ms. Kirti Dalvi is managing this scheme since December 2, 2025.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Dec-19.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Ms. Kirti Dalvi is managing 2 schemes. The performance data for the schemes which have not completed one year has not been provided.
Note: As January 31, 2026 was a non-business days, the schemes returns disclosed are as on January 30, 2026, except for Mahindra Manulife Liquid Fund and Mahindra Manulife Overnight Fund which is as of January 31, 2026.
This product is suitable for investors who are seeking*:
• Long term wealth creation and
income;
• Investment predominantly in equity
and equity related securities of large
and mid cap companies.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.